Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Deborah Collyar: What's In It for Patients?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Deborah Collyar: What's In It for Patients?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets

Long-Term Survival With vs Without Postmastectomy Chest Wall Irradiation in Breast Cancer

Newly Diagnosed AL Amyloidosis FDA Grants Traditional Approval to Regimen

Curative Treatment After First-Line Immunotherapy Improves Survival in HCC

FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas